CRRT Systems Segment to Hold Significant Share of Continuous Renal Replacement Therapy Market During 2022–2030
According to our latest study on "Continuous Renal Replacement Therapy Market Forecast to 2030 – Global and Regional Share, Trend, and Growth Opportunity Analysis – by Product, Modality, and End User," the market was valued at US$ 1.42 billion in 2022 and is projected to reach US$ 2.75 billion by 2030. The market is estimated to register a CAGR of 8.7% from 2022 to 2030. The increased demand for pediatric CRRT devices and the high prevalence of chronic diseases leading to kidney diseases are the key factors driving the market. Advancements in the CRRT systems are likely to bring new trends to the market. However, underdiagnosis of kidney diseases hampers the continuous renal replacement therapy market growth.
Modern CRRT machines are becoming compact, more efficient, and user-friendly. interface, connectivity options, and touchscreens, making it easier for healthcare professionals to use. Advancements in CRRT machine technology are key to digital healthcare as it enhance the patient-centered care, AI-driven decision support, remote alarms and notifications, telemedicine and remote monitoring, and enhanced data collection and integration. Further, cross-institutional comparisons are possible with the latest CRRT machines' automatic data collection feature. For instance, SURDIAL DX by Nipro is a state-of-the-art hemodialysis system designed to create an optimal dialysis treatment experience for patients and clinicians. Modern CRRT machines also make it possible to decrease the difference between the dose that is administered and the recommended dosage since they automatically compensate by increasing the dose by 5% every hour in accordance with the dose that is lost during repeated stops. The improving efficiency, portability, and use of modern CRRT machines with an interface, touchscreens, and connectivity choices are simplifying the job of healthcare practitioners. Thus, advancements in CRRT systems are likely to bring new continuous renal replacement therapy market trends in the coming years.
Continuous Renal Replacement Therapy Market, by Modality – 2022 and 2030
Continuous Renal Replacement Therapy Market Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product (Dialysates and Replacement Fluids, Disposables, Hemofilters, Bloodline Sets and Tubes, and CRRT Systems), Modality [Continuous Venovenous Hemofiltration (CVVH), Continuous Venovenous Hemodiafiltration (CVVHDF), Continuous Venovenous Hemodialysis (CVVHD), and Slow Continuous Ultrafiltration (SCUF)], and End User (Hospitals, Ambulatory Care Centers, Homecare, and Others)
Continuous Renal Replacement Therapy Market Size by 2030
Download Free Sample
The emerging market in the Asia Pacific is likely to create significant opportunities for the key market players to expand their businesses in the coming years. Improving healthcare infrastructure with rising expenditure and the adoption of innovative CRRT technologies bolster the continuous renal replacement therapy market size in Asia Pacific. Additionally, strategic initiatives by the market players to expand their presence in this region, including collaborations with local healthcare providers, favor the market growth in the region.
Market Segmentation:
The continuous renal replacement market analysis has been carried out by considering the following segments: product, modality, and end user.
The market, by product, is segmented into dialysates and replacement fluids, disposables, bloodline sets and tubes, CRRT systems, and hemofilters. The CRRT systems segment held the largest share of the market in 2022. The hemofilters segment is likely to register the highest CAGR in the market during 2022–2030. The hemofilters are composed of a hollow-fiber membrane that controls the volume of fluids and solutes evacuated. By eliminating solutes (waste products, electrolytes, and other molecules), CRRT hemofilter membranes imitate some of the activities of the kidney. Moreover, they may help restore fluid status and acid-base balance through their function.
The continuous renal replacement therapy market, by modality, the continuous renal replacement therapy market is segmented into continuous venovenous hemofiltration (CVVH), continuous venovenous hemodiafiltration (CVVHDF), continuous venovenous hemodialysis (CVVHD), and slow continuous ultrafiltration (SCUF). The continuous venovenous hemofiltration (CVVH) segment held the largest share of the market in 2022; however, the continuous venovenous hemodiafiltration (CVVHDF) segment is likely to register the highest CAGR in the continuous renal replacement therapy market during 2022–2030. CVVHDF employs a highly effective hemodiafilter to remove both fluid and solutes. It is the most used CRRT for treating acute kidney injury (AKI) in several countries, and it involves completely removing and replacing fluid and solutes from the blood.
The market, by end user, is segmented into hospitals, ambulatory care centers, home care, and others. In 2022, the hospitals segment dominated the continuous renal replacement therapy market share. The home monitoring segment is expected to register the highest CAGR during 2022–2030. In 2023, the US had 5,157 community hospitals, 206 federal government hospitals, and 107 other hospitals, according to the American Hospital Association. Further, the growing elderly population and the notable rise in hospital admissions for AKI are the key factors that propel the demand for CRRT systems in hospitals.
Continuous Renal Replacement Therapy Market, by Geography:
The geographic scope of the continuous renal replacement therapy market report entails North America (US, Canada, and Mexico), Europe (Spain, UK, Germany, France, Italy, and Rest of Europe), Asia Pacific (South Korea, China, India, Japan, Australia, and Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, UAE, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America). In terms of revenue, North America dominated the continuous renal replacement therapy market share. According to the Centers for Disease Control and Prevention in 2021, ~785,000 people in the US were living with end-stage kidney disease also known as end-stage renal disease; 71% out of these were undergoing dialysis while 29% had undergone kidney transplant procedures. As of 2020, there were nearly 7,500 dialysis clinics in the US. The increasing adoption of unhealthy food habits is one of the most prominent risk factor for numerous lifestyle-related disorders such as hypertension, diabetes, and kidney dysfunction. According to the US Department of Health and Human Services in 2021, 1 in 7 US adults were estimated to have CKD. Thus, the surging incidence of kidney-related disorders propels the continuous renal replacement therapy market growth in North America.
The continuous renal replacement therapy market report is focused on prominent companies such as Baxter International Inc, Asahi Kasei, Fresenius Medical Care, Medica S.p.A., Medtronic Plc, B. Braun, Nikkiso Co Ltd, Toray Medical Co Ltd, Infomed SA, and Quanta Dialysis Technologies Inc.